123 related articles for article (PubMed ID: 16546871)
1. Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
Ortega C; Faggiuolo R; Vormola R; Montemurro F; Nanni D; Goia F; Aglietta M
Acta Oncol; 2006; 45(2):216-7. PubMed ID: 16546871
[No Abstract] [Full Text] [Related]
2. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Olson KB; Hellie CM; Pienta KJ
Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw and bisphosphonates.
Durie BG; Katz M; Crowley J
N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16000365
[No Abstract] [Full Text] [Related]
4. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
6. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
7. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
8. Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis.
Raffaelli L; Scaramuzzo L; Rossi Iommetti P; Graci C; Maccauro G; Manicone PF
J Biol Regul Homeost Agents; 2010; 24(2):115-21. PubMed ID: 20487624
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S
J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
[TBL] [Abstract][Full Text] [Related]
11. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
12. Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid.
Borrás-Blasco J; Rosique-Robles D; Giner-Marco V; Galan-Brotons A; Casterá E; Costa S
J Clin Pharm Ther; 2007 Dec; 32(6):651-4. PubMed ID: 18021344
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?
Zavras AI; Zhu S
J Oral Maxillofac Surg; 2006 Jun; 64(6):917-23. PubMed ID: 16713806
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and osteonecrosis of the jaw.
Shenker NG; Jawad AS
Rheumatology (Oxford); 2007 Jul; 46(7):1049-51. PubMed ID: 17500074
[No Abstract] [Full Text] [Related]
15. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
16. Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Berruti A; Ortega C; Fusco V
Eur Urol; 2009 Mar; 55(3):e61-2. PubMed ID: 18945537
[No Abstract] [Full Text] [Related]
17. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
18. Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Kyrgidis A; Teleioudis Z; Vahtsevanos K
Eur Urol; 2009 Apr; 55(4):e72-3; author reply e74-5. PubMed ID: 18718705
[No Abstract] [Full Text] [Related]
19. Zoledronic acid induced osteonecrosis of tibia and femur.
Gupta S; Jain P; Kumar P; Parikh PM
Indian J Cancer; 2009; 46(3):249-50. PubMed ID: 19574685
[No Abstract] [Full Text] [Related]
20. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
